Last week, we gladly hosted the 33rd NKRV workshop at our premises in Petten. The mission of this Dutch Society for Clinical Radiochemistry (NKRV) is to stimulate research and education in radio(pharmaceutical)chemistry as well as the application of radiopharmaceuticals in the clinic.
After years of preparation, the FIELD-LAB facility in Petten, the Netherlands, has officially opened its doors on 7 December. This brand new facility will help accelerate the development of new nuclear medicines for the treatment of cancer.
Minister Kuipers of Health, Welfare and Sport announced today that there is full financing for the construction of the PALLAS-reactor in the North Holland town of Petten.
After many months of preparation and building, the new FIELD-LAB facility in Petten, the Netherlands, will open its doors on December 7th of this year. NRG|PALLAS has been working hard to realise the new drug discovery facility, that will help speed up the development and market launch of new nuclear drugs for cancer treatment.
NRG and TerThera signed an agreement for irradiation services in the High Flux Reactor in Petten, the Netherlands to produce Terbium-161. The non-carrier-added (NCA) Terbium-161 is produced by neutron irradiation of highly enriched Gadolinium-160 targets in the Dutch research reactor.
New essential analysis equipment for Quality Control has been installed in FIELD-LAB. This equipment will be used to perform measurements on isotopes, produced by FIELD-LAB in the near future, to establish if the isotope is up to GMP (Good Manufacturing Practice) standards and, consequently, can be used in patients.
Already in 2001, NRG supported the development of Peptide Receptor Radionuclide Therapy with carrier added Lutetium-177 (Lu-177 c.a.) by the supply of Lutetium-177 trichloride as a radiochemical. Nowadays, Lu-177 no carrier added is preferably used. “Lu-177 n.c.a. has a higher specific activity and thus radiolabeling efficiency, than lu-177 c.a.”, according to Marion Chomet, lead scientist at FIELD-LAB. Chomet and her colleagues are now fine-tuning and finalizing their custom made lutetium-177 n.c.a. process. But there are several challenges and practical considerations that they are facing.
It is game on for actinium-225 and lead-212. These two alpha-emitters can treat the same cancer and they are center stage in several researches around the world. However, only one can be the winner and conquer the market. What are the differences between these two powerhouses and which one is more likely to take the prize.
Kansen voor West visited FIELD-LAB in Petten last Wednesdag 9 November. Kansen voor West (Opportunities for West) is one of the larger subsidy providers of this project and every year they choose one of their projects for a workvisit.
Minister Kuipers of Health, Welfare and Sport announced today, that money has been set aside for the construction of the PALLAS-reactor in Petten, North Holland, in the coming years.